Zofran Actions Consolidated in Multidistrict Litigation
According to nationwide reports, families are bringing countless lawsuits against the makers of the drug Zofran and related substances, alleging that the use of the anti-nausea drug resulted in children being born with severe birth defects. As a result of the high number of Zofran and related drug lawsuits being brought, they have been consolidated in a multidistrict litigation, or MDL, in the District Court of Massachusetts in Boston. The United States Judicial Panel on Multidistrict Litigation has named the action MDL No. 2657, or In Re: Zofran (Ondansetron) Products Liability Litigation.
The prescription drugs Zofran, also known as ondansetron, and Zuplenz have been associated with severe and debilitating pregnancy complications and birth defects. Doctors initially prescribed the drugs to pregnant women to help curb the high levels of vomiting and nausea that pregnant women often experience. Studies have linked the drugs to birth defects, causing families who have suffered grave consequences as a result to bring lawsuits against the maker of the drug, GlaxoSmithKline, claiming that the company marketed the drug to the public without first obtaining appropriate U.S. Food and Drug Administration (“FDA”) approvals.